MedTrace Logo

An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

NCT01344889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4459

Last updated 2016-11-02

No results posted yet for this study

Summary

This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and ribavirin. Data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.

Conditions

  • Hepatitis C, Chronic

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Albania
  • Algeria
  • Bahrain
  • Belgium
  • Bosnia and Herzegovina
  • Brazil
  • Egypt
  • Greece
  • Hungary
  • India
  • Iran
  • Italy
  • Kuwait
  • Lebanon
  • Morocco
  • North Macedonia
  • Pakistan
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Serbia
  • Slovakia
  • South Korea
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01344889 on ClinicalTrials.gov